New charity partnership with the BioIndustry Association (BIA)

3 December 2025

Today, Wednesday 3 December 2025, the BioIndustry Association (BIA) announced Muscular Dystrophy UK as its charity partner of the year for 2026.

What does the partnership mean?

Through this partnership, the BIA will leverage the network it has fostered in the UK life sciences and biotech sector to support those affected by muscle wasting conditions.

The BIA will support us through strategic opportunities and fundraising activities over the next 12 months. The partnership will be formally launched at the BIA Gala Dinner, taking place on Thursday 29 January 2026 at the Roundhouse in Camden, London.

The partnership aims to raise the profile of muscle wasting conditions. Specifically, it will highlight the importance of having access to new treatments and receiving the right support, as well highlighting the need to improve the speed, accuracy and equity of diagnosis.

Hear from our CEO

“Being named the BioIndustry Association’s Charity Partner for 2026 is a real honour. We have set ourselves some bold ambitions over the next ten years and with the BIA’s support, we can work towards realising our vision of a world without limits for people living with muscle wasting conditions – funding more research, transforming diagnosis, improving access to new treatments, expanding our support services, and campaigning for a more equal and accessible world. This partnership will help to drive change and transform the lives of adults and children in the UK living with a muscle wasting condition.”

Andy Fletcher
Our CEO

Hear from the Managing Director of the BIA

“We’re delighted to welcome Muscular Dystrophy UK as our charity partner for 2026. This partnership is about more than fundraising – it’s about shining a spotlight on the urgent need for innovation and collaboration to improve the lives of those affected by muscle wasting conditions. Health charities are a key component of the UK’s life science innovation ecosystem, with research and expertise driven by patient insight.

“Through the strength of our sector and the connections we’ve built across industry, healthcare and government, we aim to help raise awareness, accelerate R&D by encouraging collaborative opportunities with our members, and advocate for better access to innovative clinical trials and therapies. Together with Muscular Dystrophy UK, we want to ensure that progress in science translates into tangible impact for patients and families.”

Jane Wall
Managing Director of the BIA